The development a diagnostic biomarker for adult attention deficit hyperactivity disorder: A multimodal approach
Not Applicable
- Conditions
- Attention deficit hyperactive disorder(ADHD)
- Registration Number
- JPRN-UMIN000025183
- Lead Sponsor
- Fukushima Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1) No history of illicit drug use, antidepressants (at least not over the last3 months) or other psychoactive medication/medication affecting DAT (such as buproprion) in either patients or controls. 2) A history indicating excessive nicotine or alcohol intake (>0.5 packs of cigarettes, >4 glasses of an alcoholic substance a day). 3) Exclusion criteria to MRI: presence of a pacemaker, metallic implants in high-risk areas (i.e. vessel clips) and a history of claustrophobia. 4) Subjects during pregnancy and/or lacting.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. DAT BP in the striatum (putamen, caudate nucleus, and Nucleus Accumbens,:NAc,) measured by SPECT. 2. MMN measured by ERP 3. Parameters of brain network topology measured by DT-MRI
- Secondary Outcome Measures
Name Time Method 1. Clinical evaluation for ADHD and ASD (each test will be done in all subjects including controls) 1) Conners' Adult ADHD Rating Scales (CAARS) 2) The Adult Autism Spectrum Quotient (AQ) 2. Intelligence quotient with Wechsler Adult Intelligence Scale 3. Measurements of blood concentration of monoamine metabolites; HVA, tMHPG, fMHPG, 5-HIAA